Jens Huober
A5067146231- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Ovarian cancer diagnosis and treatment
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Medical Imaging Techniques and Applications
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Risks and Factors
- PI3K/AKT/mTOR signaling in cancer
- Clusterin in disease pathology
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
Kantonsspital St. Gallen
2010-2025
Zug Cantonal Hospital
2025
Universität Ulm
2015-2024
Breast Center
2010-2024
University of St. Gallen
2008-2024
University Hospital Ulm
2015-2024
Swiss Group For Clinical Cancer Research
2012-2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2017-2023
Harvard University
2023
Dana-Farber Cancer Institute
2013-2023
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy in combination with fulvestrant women hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer previously treated endocrine therapy. Methods MONARCH 3 is double-blind, randomized phase III study of abemaciclib or placebo plus nonsteroidal aromatase inhibitor 493 postmenopausal HR-positive, HER2-negative who had no prior systemic therapy the...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
This study was aimed at detecting and characterizing circulating tumor cells (CTC) before after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer.The clinical trial GeparQuattro incorporated NT approaches (epirubicin/cyclophosphamide prior to randomization docetaxel alone, combination capecitabine, or followed by capecitabine) additional trastuzumab treatment for HER2-positive tumors. We used Food Drug Administration-approved CellSearch system CTC detection...
Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant currently available standard therapies. However, up to 30% of high-risk clinical and/or pathologic features may recurrence, many in the first few years. Superior treatment options are needed prevent and development metastases for this group patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved advanced (ABC). Efficacy safety abemaciclib ABC supported evaluation...
We characterized the incidence of central nervous system (CNS) metastases after treatment with trastuzumab emtansine (T-DM1) versus capecitabine-lapatinib (XL), and efficacy among patients pre-existing CNS in phase III EMILIA study.
We investigated disease-free survival (DFS) and overall (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer.We treated 2,072 two cycles of docetaxel, doxorubicin, cyclophosphamide (TAC) randomly assigned responders to four (n = 704) or six 686) additional TAC cycles, nonresponders 321) vinorelbine capecitabine (NX; n 301) before surgery.DFS was longer receiving × 8 than those 6 (hazard ratio [HR], 0.78; 95% CI, 0.62 0.97; P .026), TAC-NX (HR, 0.59; 0.49...
<h3>Importance</h3> The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether<i>BRCA1</i>and<i>BRCA2</i>germline mutation status affects treatment outcome remains elusive. <h3>Objective</h3> To determine whether<i>BRCA1</i>and<i>BRCA2</i>germline therapy TNBC. <h3>Design, Setting,...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in breast cancer, with mutations PIK3CA being the most common. This study investigated association between genotype and pathologic complete response (pCR) rates human epidermal growth factor receptor 2 (HER2)-positive cancer treated either dual or single anti-HER2 treatment addition to neoadjuvant chemotherapy.PIK3CA 504 tumor samples from participants GeparQuattro, GeparQuinto, GeparSixto studies were evaluated. All...